Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS As Wegovy Hits Japan Market, Novo Re-Stresses Need for Proper Use
February 26, 2024
-
REGULATORY Drug Comparisons in Promotional Activities Allowed under 4 Conditions: MHLW
February 26, 2024
-
REGULATORY Japan to Revisit Vaccine Lot Release Process to Eradicate Double Testing
February 22, 2024
-
REGULATORY New Doctor Payment Disclosure Rule to Apply to Foreign Firms with Japan Subsidiaries
February 21, 2024
-
REGULATORY Japan to End Public Aid for COVID Drugs at March-End
February 21, 2024
-
REGULATORY Xocova, Astellas’s Gastric Cancer Med Up for PAFSC Review on March 4; Pfizer’s Bispecific, RSV Jab Also on Agenda
February 20, 2024
-
BUSINESS Gilead Japan Ramping Up Sales Force with Trodelvy Now under Review
February 20, 2024
-
BUSINESS Active Pharma Hid Botched API Production, Source Reveals Details of Violations
February 19, 2024
-
BUSINESS Cancer Specialist BeiGene Set to Enter Japan Market as Early as This Year
February 16, 2024
-
BUSINESS GSK Japan Nets 11% Sales Rise in 2023, Sees 6% CAGR through 2026: President
February 15, 2024
-
REGULATORY Japan to Announce New Drug Prices on March 5
February 15, 2024
-
REGULATORY Chuikyo Issues 2024 Reform Recommendation; 1,000 Yen Premium Set for Inpatient Biosimilar Use
February 14, 2024
-
REGULATORY Japan Approves Jardiance for CKD, Label Expansion for Opdivo and More
February 13, 2024
-
BUSINESS Medac Poised to Cement Japan Foothold in RA, Eyes Rare Disease Launch Too: CEO
February 9, 2024
-
BUSINESS Mounjaro Logs 5.6 Billion Yen in Q3 YTD despite Curbed Shipments: Mitsubishi
February 8, 2024
-
REGULATORY Generic Panel to Issue Report in Spring-Summer to Drive Manufacturing Efficiency towards Stable Supplies: Official
February 8, 2024
-
REGULATORY Legal Changes on Horizon for GMP Inspection Authorities, Other Regulation Panel Topics?
February 7, 2024
-
BUSINESS 2,000 Patients Receiving Leqembi in US, 4 Times the Number on Wait List: Eisai
February 7, 2024
-
REGULATORY AMED Needs More Manpower to Fulfill Its Role as Funding Agency: President
February 6, 2024
-
BUSINESS Sumitomo to Reinforce Restructuring to Fight Deficit, First in North America: President
February 6, 2024
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…